Companies · Biotechnology

Apollo Endosurgery, Inc.

AUSTIN · Biotechnology

Diligence memoA one-page analyst read on Apollo Endosurgery, Inc. — recommendation, valuation, rhythm, risks.
$62.4M
Total raised · real
4
Rounds
1.2×
Latest step-up
Top 16%
Sector rank · raised
Series B
Latest stage · inferred · Tue Jul 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Apollo Endosurgery, Inc. looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 1.57× the median modeled value of Series B Biotechnology companies in 2019–2021 (118 peers) — value vs value, same stage and era.
Dormant
  • Last raise 5.9 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Apollo Endosurgery, Inc. is one of 4291 Biotechnology companies tracked from AUSTIN. By capital raised it ranks in the upper tier (ahead of 85% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
18
Investors (latest)
2020-07-21
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$250M$500M$750M$1.0BSeries A · 2010-11-16 Raised $4.9M (real) Modeled valuation $177M (est)$4.9M$177MSeries A2010Series A · 2014-09-25 Raised $13M (real) Modeled valuation $453M (est)$13M$453MSeries A2014Series B · 2019-08-12 Raised $20M (real) Modeled valuation $794M (est)$20M$794MSeries B2019Series B · 2020-07-21 Raised $25M (real) Modeled valuation $968M (est)$25M$968MSeries B2020+$13M+$20M+$25MCumulative $62M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$4.9M · 2010
Series A extension$12.5M · 2014
Series B$20.0M · 2019
Series B extension$25.0M · 2020

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$967.9M
Base estimate est.
$50.0M
Conservative case
$3.7B
Upside case
$138.8M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series A · modeled $176.6M · 2010-11-162010Series A · modeled $452.9M · 2014-09-25Series B · modeled $793.8M · 2019-08-12Series B · modeled $967.9M · 2020-07-212020
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
54%
Survival probability
36% low · 66% high
1.54×/yr
Annual markup
1.86×/yr upside case
5.9 yr
Elapsed time used
5.9 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
39 mo
Avg between rounds
$6.4M/yr
Capital velocity
15.6 yr
On record since
2010
First round
4
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 8.7× above median
This company$62.4M
Sector median$7.2M
Latest round — vs other Series B rounds in sector (real $, this stage) 1.4× above median
This company$25.0M
Sector median$17.5M
Modeled value — vs sector median (estimate, all stages) 15× above median
This company$967.9M
Sector median$64.2M

Raised more than 85% of sector peers (real $). Modeled value above 89% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #15 of 118.

This companyCohort peer
$100.0M$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Pandion Therapeutics Holdco LLC · Series B Raised $40.0M · modeled $1.6B (est)Ocular Therapeutix, Inc · Series B Raised $81.0M · modeled $1.5B (est)Insilico Medicine Cayman TopCo · Series B Raised $36.8M · modeled $1.5B (est)Purigen Biosystems, Inc. · Series B Raised $61.9M · modeled $1.4B (est)Lucira Health, Inc. · Series B Raised $32.5M · modeled $1.3B (est)Peptilogics, Inc. · Series B Raised $40.9M · modeled $1.2B (est)Nanotech Energy, Inc. · Series B Raised $31.6M · modeled $1.1B (est)Windtree Therapeutics Inc /De/ · Series B Raised $104.5M · modeled $1.0B (est)Liminal BioSciences Inc. · Series B Raised $67.1M · modeled $1.0B (est)Palladio Biosciences, Inc. · Series B Raised $28.0M · modeled $1.0B (est)Faze Medicines, Inc. · Series B Raised $30.4M · modeled $998.4M (est)Inivata Ltd · Series B Raised $25.0M · modeled $992.2M (est)Apollo Endosurgery, Inc. (this company) Raised $62.4M · modeled $967.9M (est)Apollo Endosurgery, Inc.
CompanyStageRaised · realValue · estvs peer med.
Pandion Therapeutics Holdco LLCSeries B$40.0M$1.6B2.58×
Ocular Therapeutix, IncSeries B$81.0M$1.5B2.42×
Insilico Medicine Cayman TopCoSeries B$36.8M$1.5B2.37×
Purigen Biosystems, Inc.Series B$61.9M$1.4B2.22×
Lucira Health, Inc.Series B$32.5M$1.3B2.10×
Peptilogics, Inc.Series B$40.9M$1.2B1.90×
Nanotech Energy, Inc.Series B$31.6M$1.1B1.82×
Windtree Therapeutics Inc /De/Series B$104.5M$1.0B1.71×
Liminal BioSciences Inc.Series B$67.1M$1.0B1.67×
Palladio Biosciences, Inc.Series B$28.0M$1.0B1.63×
Faze Medicines, Inc.Series B$30.4M$998.4M1.62×
Inivata LtdSeries B$25.0M$992.2M1.61×
Apollo Endosurgery, Inc. this companySeries B$62.4M$967.9M1.57×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$4.9M2010-11-16$22.2M$176.6M85%
Series A$12.5M2014-09-25$56.9M$452.9M85%
Series B$20.0M2019-08-12$111.1M$793.8M90%
Series B$25.0M2020-07-21$138.8M$967.9M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$4.9M2010-11-16
    • First recorded raise — entered as Series A.
    • 52 investors on this round.
  2. Series A$12.5M2014-09-25
    • Raised again after 46 mo — slower than the ~14 mo sector norm.
    • Round 2.6× larger than the prior — scaling up.
    • Switched to Rule 506(b) (was Rule 06).
    • 3 investors on this round.
  3. Series B$20.0M2019-08-12
    • Raised again after 59 mo — slower than the ~14 mo sector norm.
    • Round 1.6× larger than the prior — scaling up.
    • 18 investors on this round.
  4. Series B$25.0M2020-07-21
    • Raised 11 mo later, in step with the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 18 investors on this round.
Intelligence
2023 ~Q4
Modeled next raise · ~39mo cadence
$31.2M
Modeled next size est.range $25.0M$49.9M
1.2×
Last step-up
$6.4M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Rick Anderson3 other2019-08
Daniel L. Kisner2 other2014-09
John Barr2 other2019-08
STEFANIE CAVANAUGH2 other2019-08
Bret Schwartzhoff1 other2019-08
Bruce C Robertson1 other2019-08
Matthew S. Crawford1 other2019-08
Todd Newton1 other2019-08
Charles A Mathews2010-11
Christopher C. Gostout2019-08
Christopher J. Gostout2020-07
Daniel H Petree2010-11
David C. Pacitti2019-08
Donald R Swortwood2010-11
Gary J G Atkinson2010-11
Jeffrey A Ferrell2010-11
John C. Molesphini2019-08
John J. Molesphini2020-07
Julie C. Shimer2019-08
Julie J. Shimer2020-07
R. Kent D. McGaughy, Jr.2019-08
Scott R Pancoast2010-11
William D. McClellan2019-08
Registry & provenance

Apollo Endosurgery, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1251769
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Apollo Endosurgery Us IncBiotechnologySeries C$175.9M$2.2Bnetwork5 shared operators · same sector
Histogen Inc.BiotechnologySeries B$94.9M$82.8Mnetwork1 shared operator · same sector · same stage
CardioFocus, Inc.BiotechnologySeries B$153.2M$351.9Mnetwork1 shared operator · same sector · same stage
Cell Biosciences IncBiotechnologySeries B$62.3M$516.0Msame sector · same stage
4Tech, Inc.BiotechnologySeries B$62.3M$1.1Bsame sector · same stage
Taligen Therapeutics IncBiotechnologySeries B$62.1M$1.4Bsame sector · same stage
Purigen Biosystems, Inc.BiotechnologySeries B$61.9M$1.4Bsame sector · same stage
Seventh Sense Biosystems, Inc.BiotechnologySeries B$62.9M$732.6Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Apollo Endosurgery Us IncBiotechnologySeries C$2.2B99%
Arc Endosurgery Inc.BiotechnologySeed$6.3M89%
Origin Endoscopy Inc.BiotechnologySeed$10.0M85%
Astro Health IncBiotechnologyPre-Seed$170K85%
Artio Medical, Inc.BiotechnologySeries B$70.7M85%
Santa Ana Bio, Inc.BiotechnologySeries B$150.4M85%
Jupiter Biomedical Research, Inc.BiotechnologyPre-Seed$843K84%
EndoTheia, Inc.BiotechnologyPre-Seed$2.1M84%
Frequently asked
How much funding has Apollo Endosurgery, Inc. raised?
Apollo Endosurgery, Inc. has raised approximately $62.4M in disclosed capital across 4 recorded financing rounds, aggregated from public filings.
What is Apollo Endosurgery, Inc.'s estimated valuation?
Provath's modeled valuation for Apollo Endosurgery, Inc. is approximately $967.9M (modeled range $50.0M–$3.7B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Apollo Endosurgery, Inc. at?
Apollo Endosurgery, Inc.'s latest modeled financing stage is Series B. Its most recent recorded round closed around Tue Jul 21.
What does Apollo Endosurgery, Inc. do and where is it based?
Apollo Endosurgery, Inc. operates in the Biotechnology sector, based in AUSTIN.
Explore related

See where Apollo Endosurgery, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Apollo Endosurgery, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.